Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Our main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland.
Behind Cinclus Pharma stands an experienced team with deep knowledge in different aspects of drug development and business development with experience from big pharma as well as biotech.
Cinclus Pharma AG is 100% owned by Cinclus Pharma Holding AB, based in Sweden.